2004 Winter report

CIKA is committed to providing funding for research into solid tumors

2004 Winter report - Cancer in Kids @ RCH - CIKA

2004 saw CIKA collaborate with the Leukemia Association of the Royal Children's Hospital (LARCH) in funding research in the Molecular Oncology laboratory. The following item appeared in CIKA's Winter Newsletter.

Since the inception of CIKA 24 years ago we, have been very committed to funding research at
the Royal Children's' Hospital.

Late in 2003 CIKA was made aware that there was a shortfall in funding for research at the Molecular Oncology Laboratory. At the November CIKA meeting the committee considered a presentation from Dr Elizabeth Algar, in which she presented an overview of the work being undertaken by the lab under her direction, and the funding needed to ensure its continuation in the short term. The CIKA committee agreed to fund this important work in conjunction with the Leukamia Association of the Royal Children's Hospital (LARCH). Detailed below is an overview of the research that CIKA is funding.

The Molecular Oncology Laboratory provides a molecular diagnostic testing service to assist in the clinical management of solid tumour and leukemia patients. The aim of the laboratory is to enable paediatric cancer patients to benefit from the application of "state of the art" technologies in the management of their disease. This involves using current knowledge of the chromosomal and genetic changes that have arisen in a cancer cell to aid accurate disease diagnosis and to give an idea of disease prognosis. This information is required in order for optimal therapies to be given. Knowledge of the chromosomal or genetic changes in a cancer cell, identified at diagnosis, also provides a tool to distinguish the cancer cell from other normal cells. This is done in the laboratory using a technology known as the polymerase chain reaction or PCR, and has an especially important application in the monitoring of leukemia during therapy.

It is likely in the future that new therapies for the treatment of both solid tumors and leukemias will be based on targeting the genetic alterations that are unique to cancer cells and that are not present in normal cells. It is clear that molecular oncology, or understanding and identifying the genetic changes in cancer, will play an increasingly important role in cancer diagnosis and treatment in the future.

The head of the Molecular Oncology laboratory is Dr. Elizabeth Algar. The only salaried staff member of the laboratory, Dr. Algar has had fourteen years of post-doctoral experience in the area of paediatric cancer genetics. She is one of few people in Australia with a breadth of experience in this specialized field. In 2001 she initiated the transformation of the Molecular Oncology laboratory from a basic research laboratory into one providing both applied research and diagnostic testing for paediatric cancers and cancer syndromes. Her vision is to see the Molecular Oncology laboratory develop into a specialized laboratory providing molecular genetic testing for the paediatric cancer population, in Victoria initially, and ultimately for the Australian population.

However, for its continued operation the Molecular Oncology laboratory is heavily reliant on philanthropic funds. This is particularly acute in its present phase. An enormous amount of ground work has been put in to get the laboratory to its present operational state and to apply for NATA accreditation status (which will hopefully be granted this year). Whilst the laboratory is currently supported through CIKA and LARCH at its present funding and staffing levels the laboratory cannot expand the range of tests it can offer nor improve result delivery times. In addition, the current situation limits the opportunity that Dr. Algar might otherwise have to seek new potential sources of funding. Additional staffing and financial security to enable long-term planning are desperately needed.

Dr David Ashley,
Head of Clinical Haematology & Oncology